IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
Study Locations
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Recruiting
- Wollongong Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- Cancer Research SA
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230022
- Recruiting
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Beijing, Beijing Municipality, China, 100853
- Recruiting
- Chinese People's Liberation Army General Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Recruiting
- Fujian Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Fuzhou, Fujian, China, 350005
- Recruiting
- First Affiliated Hospital, Fujian Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Recruiting
- The Affiliated Tumor Hospital of Guangxi Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Recruiting
- Harbin Medical University Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang, Henan, China, 455100
- Recruiting
- Anyang Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Luoyang, Henan, China, 471003
- Recruiting
- The First Affiliated Hospital of Henan University of Science and Technology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, China, 450052
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital, Central South University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330029
- Recruiting
- Jiangxi Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200120
- Recruiting
- Shanghai East Hospital, Tongji University School of Medicine
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital, Sichuan University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Sichuan Cancer Hospital & Institute
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- START Center for Cancer Research
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Recruiting
- START Center for Cancer Research
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas, Texas, United States, 75039
- Recruiting
- NEXT Oncology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Phone Number: 650-370-0985
- Email: ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Active, not recruiting
- Virginia Cancer Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open-label: IBI3001 monotherapy
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with adverse events
Time Frame: 24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
Time Frame: 24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
Time Frame: 24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Time Frame: 24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
Time Frame: 24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
Time Frame: 24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
Time Frame: 24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
Time Frame: 24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
Time Frame: 24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
Time Frame: 24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
Time Frame: 24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
Time Frame: 24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
Time Frame: 24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
Time Frame: 24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
Time Frame: 24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
Time Frame: 24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
Time Frame: 24 months
|
Overall survival. |
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CIBI3001A101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.